Clinical Trial Update: Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel, estramustine, and thalidomide in metastatic castration-resistant prostate cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Estracyt (estramustine phosphate)
• Thalomid (thalidomide)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED